Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

NCT04617860 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Huntington Disease

Interventions

DRUG: WVE-120102

Sponsor

Wave Life Sciences Ltd.